Fisher & Paykel Healthcare (NZSE:FPH) Cash And Cash Equivalents : NZ$71 Mil (As of Sep. 2023)

View and export this data going back to 1979. Start your Free Trial

What is Fisher & Paykel Healthcare Cash And Cash Equivalents?

Fisher & Paykel Healthcare's quarterly cash and cash equivalents increased from Sep. 2022 (NZ$69.80 Mil) to Mar. 2023 (NZ$121.00 Mil) but then stayed the same from Mar. 2023 (NZ$121.00 Mil) to Sep. 2023 (NZ$70.50 Mil).

Fisher & Paykel Healthcare's annual cash and cash equivalents declined from Mar. 2021 (NZ$97.30 Mil) to Mar. 2022 (NZ$89.90 Mil) but then increased from Mar. 2022 (NZ$89.90 Mil) to Mar. 2023 (NZ$121.00 Mil).

Fisher & Paykel Healthcare Cash And Cash Equivalents Historical Data

The historical data trend for Fisher & Paykel Healthcare's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fisher & Paykel Healthcare Cash And Cash Equivalents Chart

Fisher & Paykel Healthcare Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Cash And Cash Equivalents

Get a 7-Day Free Trial

48.20

67.10

97.30

89.90

121.00

Fisher & Paykel Healthcare Semi-Annual Data
	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Cash And Cash Equivalents	Get a 7-Day Free Trial															103.20	89.90	69.80	121.00	70.50

Fisher & Paykel Healthcare Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Fisher & Paykel Healthcare (NZSE:FPH) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Fisher & Paykel Healthcare Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Fisher & Paykel Healthcare's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Fisher & Paykel Healthcare (NZSE:FPH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Fisher & Paykel Healthcare Corp Ltd (NZSE:FPH) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

FSPKF:USA FPLB:Germany FPH:Australia

Address

15 Maurice Paykel Place, East Tamaki, Auckland, NTL, NZL, 2013

Website

https://www.fphcare.com

Fisher & Paykel Healthcare is one of the three largest respiratory care device companies globally. It is the market leader in hospital use humidifiers, masks and related consumables and the number three player in the at-home treatment of sleep apnoea using respiratory devices. Both the hospital and homecare markets for respiratory devices are growing strongly in the developed markets in which Fisher & Paykel has a presence. The company earns 42% of its revenue in the U.S., 32% in Europe, 18% in Asia-Pacific and the remaining 8% in emerging markets. Fisher conducts its own R&D and has thousands of patents and pending applications. It manufactures in New Zealand and Mexico and has a multichannel distribution model.